TTK Healthcare is a diversified Indian consumer and healthcare company that has spent nearly seven decades putting everyday products - from infant gripe water to condoms and heart valves - into Indian households. Born in 1958 and part of the century-old TTK Group, the company fundamentally reshaped itself in 2022 by selling its human pharma division, exiting the prescription-drug business to focus entirely on a portfolio of branded consumer goods, medical devices, animal health, and foods. The recurring approach across these businesses is to take a product that was once imported or expensive, make it in India at an affordable price, and distribute it through a proprietary network that reaches over 6,000 dealers - the same philosophy of “Quality Products at Affordable Prices” that has guided the company from the start.
Business segments
Five engines at different stages - a consumer-products cash cow, a condom-and-pleasure platform with global supply contracts, a medical-devices bet on import substitution, an animal-health challenger, and a foods operation built on manufacturing innovation - each run through a shared pan-India distribution backbone.
1. Consumer Products: the household brands that fund everything else
A portfolio of legacy and new FMCG brands - led by a century-old infant gripe water - sold through an exclusive network of over 6,000 dealers, generating the steady demand that anchors the company.
- A legacy brand that keeps growing - Woodward’s Gripewater, positioned as a “Tummy Care Expert” for infants, crossed Rs.100 crores in sales and hit an all-time high volume of more than 4,50,000 cases, making it the division’s heavyweight.
- A deodorant built on a safety promise - EVA targets young women with a “No Aluminium, No Alcohol” proposition, and its roll-on format won a Nielsen Breakthrough Innovation Award, though the brand is now navigating a format shift as aerosol growth slows.
- A home-care challenger built from scratch - The Good Home range, spanning air fresheners, drain cleaners, and cleaning tools, hit roughly Rs.12 crores in its first year and has since expanded to 15 SKUs, with mops, toilet brushes, and kitchen wipers added in a second phase.
- The distribution moat - sales to dealers and distributors account for 93.59% of total company sales, and this exclusive network is the launchpad for every new product the division introduces.
2. Protective Devices and Pleasure Products: the condom factory with a consumer brand on top
One of the world’s WHO-prequalified condom manufacturers, running a three-layer model - branded sales under Skore, contract manufacturing for a global brand, and institutional supply to aid agencies - while building a direct-to-consumer pleasure business on the side.
- The WHO pre-qualification is the entry ticket - the company is one of the pre-qualified suppliers under the WHO-UNFPA scheme, a mandatory requirement for supplying to international aid agencies and participating in global tenders.
- Three revenue streams from the same factory - the Puducherry and Virudhunagar plants produce condoms for the company’s own Skore brand, for a leading international brand’s India and overseas requirements, and for institutional buyers like aid agencies.
- A pleasure business built on e-commerce - the Skore and MsChief brands have strengthened the company’s position as a leading player in the pleasure products category online, while Love Depot, a direct-to-consumer “pleasure e-Superstore,” stocks its own brands alongside international names like We-Vibe and Satisfyer, using first-party customer data to incubate new products.
- International certifications stack up - the Protective Devices Business holds BSI, CE Mark, South African Bureau of Standards, Forest Stewardship Council, SEDEX, and BSCI certifications, all maintained through quality audits without major non-conformances.
3. Medical Devices: the import-substitution bet on hearts and knees
Indigenously developed titanium heart valves and orthopaedic implants, priced competitively against imported alternatives, with government “Make in India” initiatives creating a tailwind.
- A heart valve made in India - the TTK Chitra Titanium Heart Valve is manufactured in-house, and an improved version, the TC2, has completed a 40-patient pilot study at SCTIMST with three-year follow-up results showing excellent performance, with larger pivotal studies of roughly 400 patients planned.
- Knee implants moving into new markets - a new fixed-bearing knee implant called “Citius” was introduced in select markets and roughly 350 surgeries were completed during the year, while TiN-coated implants improved product margins.
- Hip implants with a German ceramic edge - the hip business registered healthy growth with increased adoption of a Ceramic Head option imported from Ceramtec, Germany, and a Revision Hip Implant system is in the pipeline.
- Government schemes open the door - the Ayushman Bharat medical insurance scheme is expected to increase demand for heart valves and ortho implants, and the division’s growth is driven by expanding its distribution network and team footprint in line with market potential.
4. Animal Welfare: a veterinary challenger across four species
A veterinary pharmaceuticals and feed-supplements business structured into four sub-divisions - livestock, poultry, aquaculture, and pet care - promoted through a “Farm Approach Program” that bundles flagship brands.
- Four animals, four sub-brands - the division is split into Bovianim (livestock), Gallus (poultry), Aquanim (aquaculture), and Companim (pet care), each with its own focus and field force.
- A flagship bundle called OTON - the brands Orcal-P, Tefroli, Ossomin, and Nutrivel are promoted collectively through prescription support and the Farm Approach Program, giving the division a unified selling story for veterinarians.
- Pet care gets its own team - Companim was made a separate vertical with a dedicated National Sales Head and expanded field team, and the company is relaunching its Hug&Wag pet cosmetics brand while developing Waggy Bites pet treats through outsourcing and imports.
- Aquaculture growing fast from a small base - Aquanim achieved roughly 33% growth, having crossed Rs.1 crore in sales in its first year of operation.
5. Foods: the manufacturing innovator in ready-to-fry snacks
A processed-foods operation running two plants with in-house R&D, pioneering products for healthy snacking - ready-to-salt roasting, hot-air popping, and mechanical popping - for domestic, institutional, and export customers.
- Two plants with R&D at the core - the Hosakote (Karnataka) and Jaipur (Rajasthan) plants both have R&D capabilities, and the Hosakote centre commercialized four new products in the year with a focus on protein-rich and health-oriented items.
- Pioneering low-oil snack concepts - the company has developed products for ready-to-salt roasting, hot-air popping, and mechanical popping, targeting the trend toward healthier snacks with less oil.
- Non-GMO certification as a differentiator - both plants received the global Non-GMO Project’s Verified Certification for one product each, a credential that matters for export and health-conscious buyers.
- Capacity stretched, so outsourcing is expanding - the Jaipur plant reached almost 100% capacity utilization, and the company is expanding outsourcing to add more categories.
Group structure and partners
A standalone listed company with no subsidiaries, controlled by the promoter group with a 74.56% stake, and reliant on a small set of global partners for critical medical-device components and international aid-agency contracts.
- No subsidiaries, no joint ventures - TTK Healthcare operates as a single listed entity with no holding, associate, or joint venture companies, making its structure unusually simple for a diversified business.
- The TTK monogram is licensed, not owned - the company pays half-a-percent of net sales to M/s T T Krishnamachari & Co. for the right to use the “ttk monogram,” a mark built over several decades.
- The pharma exit was a clean break - the Human Pharma Division was sold in 2022 to BSV Pharma for Rs.805 crores, with 74% in cash and 26% in equity that was subsequently sold to Bharat Serums and Vaccines upon regulatory clearance, leaving the company with only its five continuing segments.
- A failed delisting attempt - the promoters launched a voluntary delisting offer in April 2023 to take the company private, citing single-digit margins and the need for long-term investment with uncertain payoffs, but the reverse book-building process did not succeed.
- Key global dependencies - Ceramtec of Germany supplies ceramic heads for hip implants, a Russian manufacturer supplies CardiaMed heart valves, and WHO-UNFPA pre-qualification governs access to the institutional condom business, while wind energy for the Virudhunagar factory and the Foods Factory at Hosakote comes through agreements with Dahila Green Energy and Renew Wind Energy respectively.